Hepatitis B Vaccine Market - By Type (Single Antigen Vaccine, Combination Vaccine), By End-use (Hospitals, Clinics) & Forecast 2023 - 2032

Hepatitis B Vaccine Market - By Type (Single Antigen Vaccine, Combination Vaccine), By End-use (Hospitals, Clinics) & Forecast 2023 - 2032

Hepatitis B Vaccine Market Size

Hepatitis B Vaccine Market size accounted for USD 3.3 billion in 2022 and is estimated to grow at 5.1% to reach USD 5.7 billion by 2032. Growing prevalence of chronic infection, liver cirrhosis and liver cancer will positively influence the market growth.
 

For instance, in 2019, according to the World Health Organization (WHO), 296 million people were living with chronic hepatitis B infection with 1.5 million new infection cases are registered each year. This indicates that there will huge number of patient pool infected with hepatitis B viral infection every year globally. The availability of effective preventive vaccines offering immunity against aforementioned diseases will offer unprecedented growth opportunities to the market.
 

Hepatitis B vaccine is a preventive vaccine that provides immunization against the hepatitis B virus (HBV). It is designed to stimulate the immune system to produce antibodies against the hepatitis B surface antigen (HBsAg), a protein found on the surface of the virus. The vaccine is typically administered through intramuscular injection and can be given as a single antigen vaccine or as a part of combination vaccines that protect against multiple diseases. It is recommended for infants, children, adolescents and adults that are at risk of HBV infection. It is also a routine part of immunization programs in many countries.
 

COVID-19 Impact

The COVID-19 pandemic has severely impacted the global economies with all the sectors witnessing a significant slump during 2020. The healthcare sector was one of the most severely impacted sectors during the pandemic owing to tremendous pressure on the healthcare systems to contain the spread of infection. Increasing focus on COVID-19 vaccination efforts lead to the disruptions in routine immunization programs, including hepatitis B vaccination campaigns. These disruptions have led to a decrease in vaccination rates and a potential slowdown in the market growth.

The strain on healthcare systems and resources during the pandemic has also affected the production, distribution, and availability of hepatitis B vaccines. Also, uncertainty and economic challenges caused by the pandemic have further impacted healthcare budgets and priorities, potentially leading to a decreased investment in hepatitis B vaccination programs, thereby negatively impacting the market in 2020.
 

Hepatitis B Vaccine Market Trends

Rising government initiatives, policies and awareness programs have played a significant role in promoting hepatitis B vaccination. Increasing number of hepatitis B infections and deaths has significantly highlighted the importance of preventing hepatitis B infection and its associated health burdens. Various governments have implemented numerous strategies to increase vaccine coverage including mandating hepatitis B vaccination for infants, children, and high-risk populations. Integrating the vaccine into routine immunization schedules and providing financial support for vaccination programs is expected to boost the market share.
 

For instance, in 2018, according to the Ministry of Health and Family Welfare, Government of India has launched National Viral Hepatitis Control Program. This program is aimed to control and manage hepatitis B and hepatitis C infections. Thus, such government initiatives and awareness programs is anticipated to foster the industry outlook.
 

Hepatitis B Vaccine Market Restraint

Stringent regulatory approval processes for hepatitis B vaccines may significantly impede the hepatitis B vaccine industry expansion. The complex and rigorous regulatory requirements leads to delay the introduction of new vaccines and limit the entry of new players into the market. The lengthy approval processes increase the time and costs associated with vaccine development and commercialization, thereby hindering the market progress.
 

Also, compliance with stringent regulations necessitates extensive clinical trials, safety evaluations, and manufacturing standards can pose challenges for small scale companies with limited resources. These regulatory hurdles can slow down innovation, limit competition and ultimately restrict the availability and accessibility of hepatitis B vaccines, thereby impacting the market dynamics.
 

Hepatitis B Vaccine Market Analysis

By type, the hepatitis B vaccine market is classified into single antigen vaccine and combination vaccine. The combination vaccine segment accounted over 65% of the market share in 2022 and is projected to witness robust growth over the analysis timeframe. Hepatitis B combination vaccines are formulated to provide protection against multiple diseases in a single shot, reducing the number of injections required for immunization. Also, combination hepatitis B vaccine is the combination of hepatitis B vaccine with other relevant antigens, such as those for diphtheria, tetanus, pertussis, other infections. These vaccines offer convenience, increased compliance, and improved vaccination coverage rates.
 

Based on end-use, the hepatitis B vaccine market is segmented into hospitals, clinics and others. The hospitals are projected to register USD 3.6 billion in 2032. This is owing to the primary vaccination dose administration to new-borns infants before the discharge from the hospitals as new-born infants are at a high risk of acquiring hepatitis B infection. Also, hospitals offer accessibility and convenience for individuals seeking hepatitis B vaccination during their regular visits for healthcare needs. Furthermore, developed infrastructure and well-established storage facilities contributes to streamlined operations and reduces the risk of vaccine shortage and wastage in the hospital.
 

North America hepatitis B vaccine market accounted for over 40.6% business share in 2022 and is anticipated to grow at considerable growth rate during the forecast timeframe. Increasing prevalence of hepatitis B infections coupled with the increasing population at risk, including newborns, healthcare workers among others is expected to fuel the market growth in the region. Also, growing awareness pertaining to the importance of immunization and preventive healthcare practices is projected to fuel the market demand.
 

Increasing investments in R&D to enhance vaccine efficacy will reduce the number of doses required, hereby significantly proliferate the market growth. Furthermore, rising government initiatives for promoting education and vaccination campaigns to enhance vaccine coverage rates will significantly drive the value in the North America region.
 

Hepatitis B Vaccine Market Share

Major market players operating in the hepatitis B vaccine market include

• Merck & Co., Inc
• Sanofi S.A.
• GlaxoSmithKline plc.
• Dynavax Technologies Corporation

These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
 

Hepatitis B Vaccine Market News

• In August 2021, Sanofi acquires Translate Bio, Inc. This strategic acquisition was aimed at deployment of mRNA technology across vaccines and therapeutics development. This strategy helped the company to maintain long-term business relations and outreach to untapped economies.
   
• In June 2021, Merck and Sanofi’s launched their partnership bases VAXELIS, first and only six-in-one pediatric combination vaccine in the U.S. market. VAXELIS is indicated for active immunization to help prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type B. This strategy helped the company to strengthen its revenue stream and consolidate market position.
   

The hepatitis B vaccine market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Type

• Single Antigen Vaccine
• Combination Vaccine

By End-use

• Hospitals
• Clinics
• Others

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Sweden
  • The Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Indonesia
  • Philippines
  • Malaysia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Columbia
  • Chile
  • Peru
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Iran
  • Rest of MEA